← All trials
NCT04278963
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Jan 31, 2021
- First posted
- Feb 20, 2020
- Last posted
- Mar 3, 2020
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- Hubei University of Chinese MedicineOverall official - principal investigator
- Yangtze University Health Science CenterOverall official - principal investigator
- Jingzhou Hospital of Traditional Chinese MedicineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.